Is PET-CT Needed for — Early Breast Cancer?

No — and the absence of a PET request is the correct clinical decision, not an oversight. For Stage I and II breast cancer, guidelines from NCCN, ASCO and ESMO specifically advise against routine PET-CT. Requesting one will not improve your staging accuracy and introduces the risk of a misleading result that triggers unnecessary investigations. If you are uncertain why a particular test was or was not ordered, ask your oncologist to explain the staging plan. That is a reasonable question and you deserve a clear answer.

An imaging centre can offer a scan, but it cannot decide whether that scan is clinically appropriate for your situation. For early-stage breast cancer, evidence does not support PET-CT as a staging tool, and guidelines specifically advise against it. A suspicious finding at this stage is more likely to be a false alarm, leading to further biopsies, anxiety and delays to treatment. Your oncologist decides which investigations are needed. If you are uncertain, raise it at your next appointment before booking anything.

PET-CT is part of standard staging for locally advanced breast cancer — Stage III — and for metastatic breast cancer, where finding all sites of disease and monitoring treatment response are the central questions. It is also used when there is a clinical suspicion of recurrence after early-stage treatment. Your oncologist will order it when the clinical question is one that PET-CT is well suited to answer.

Yes. PET-CT has limited ability to detect small deposits of cancer in the axillary lymph nodes — the nodes near the armpit that early breast cancer most commonly reaches first. Sentinel lymph node biopsy is significantly more sensitive for this question. PET also relies on metabolic activity, so slow-growing tumours and small lesions may not show clearly. This is a core reason why surgical axillary assessment remains the standard in early disease.

A false positive means the scan shows activity that looks suspicious but turns out not to be cancer on further investigation. This leads to additional biopsies, repeat imaging, and sometimes a delay of several weeks before your main treatment can begin — all to rule out something that was never there. The anxiety during that wait is real. In early breast cancer, where the probability of distant spread is low, the risk of a false positive is high enough that guidelines specifically advise avoiding routine PET.

Yes, when it is clinically indicated. CION coordinates PET-CT through partner imaging centres for patients with locally advanced or metastatic breast cancer, and for those where recurrence is suspected. For early-stage breast cancer, your CION oncologist will recommend the investigations that match your specific stage and tumour features. PET-CT will be part of that plan when it is the right test for the question being asked.